Board of Directors

  • Michael Atkin,
    Chairman of the Board

    Mr. Atkin has over 30 years of experience in life sciences as an entrepreneur, start-up executive, leader and manager in the pharmaceutical and biotechnology industries, and in advancing early stage research towards commercialization based on satisfying unmet medical needs.

    Mr. Atkin is President of Syzent Partners Ltd. ("Syzent"), a consulting firm in life sciences based in Montreal, QC. Prior to founding Syzent in 2008, Mr. Atkin was Executive Chair and subsequently CEO of Ulysses Pharmaceuticals, focused on overcoming antibiotic resistance. He was previously the founding CEO of Aegera Therapeutics, an apoptosis control company formed by the merger of McGill spinout Exogen Neurosciences with Apoptogen, where he raised $33m in two financing rounds, and advanced two novel first-in-class drugs to the clinic. At the helm of Aegera, Mr. Atkin advanced multiple technology and product partnerships with major pharmaceutical companies, generating several million dollars in revenues.

    Mr. Atkin was elected Chairman of the Board of antibiotic chemistry firm Sopharmia Inc in St. Joseph, Missouri in 2012. In 2015, Sopharmia intellectual property was acquired by Gladius Pharmaceuticals, which announced a $4m seed financing. Mr. Atkin served as CEO of Gladius from 2015 to 2019. Mr. Atkin serves on the board of a Université de Montréal spin-out company, Affinité Instruments, focused on laboratory and diagnostic tests.

    Earlier in his career, Mr. Atkin held senior executive positions in product development and licensing at Bristol-Myers Squibb Company and Lederle International, now part of Pfizer. He holds an MBA from Columbia University's graduate school of business (New York, USA) and a BA from the University of Kent at Canterbury (Great Britain).

  • Steven Saviuk,

    Mr. Saviuk has an extensive background in finance and venture capital investing including a number of successful health science companies. He co founded Valeo Pharma in 2003 and has served as its President and CEO since its inception and has overseen its transformation from its early years as an in licensor of established brands to a fast growing full service Canadian pharmaceutical company.

  • Brent Norton, MD,

    Dr. Norton is a leader in the Life Science industry with operational and Director experience across several successful enterprises which achieved significant multiples for investors. Dr. Norton founded PreMD, completing IPO's and listings on both TSX and AMEX. Operationally, he has built R&D and commercial operations, led transactions with AstraZeneca, Atherogenics, Eli Lilly, L'Oreal, Parke Davis/Pfizer, etc., and taken products through the FDA to global out-licensing with Johnson & Johnson. He is a founding Director of Novadaq Technologies (TSX:NDQ, NASDAQ:NVDQ), one of Canada's most valuable medical companies. Dr. Norton has been an active member of several BOD's, public and private, in both Canada and the US. He is a Venture Partner at Lumira Capital, a member of the Research Committee for CAMH, an Advisory BOD member for the Ivey International Centre for Health Innovation, and a Past-President and Director of the Osler Bluff Ski Club and Director of Alpine Ontario.

  • Tom Wright,

    Tom Wright is an accomplished and respected business and community leader, with extensive experience in the North American, Australian and New Zealand sports/entertainment industry that spans more than 35 years. Prior to the UFC, he was Managing Director of Level 5 Strategic Brand Advisors, one of Canada's foremost business and brand strategy firms. Before serving four years as Commissioner for the Canadian Football League from 2002 through 2006, he was the President and CEO for Salomon North American, President adidas Canada LTD and President of Spalding Canada LTD. He has also been significantly involved with Special Olympics Canada as a volunteer for more than 30 years and served as the organization's National Board Chairman.

    Tom holds a Bachelor of Physical and Health Education degree from the University of Toronto as well as his MBA from The Schulich School of Business at York University. Tom recently concluded the Directors Education Program at U of T's Rotman School of Management, a program focused on board governance offered through the Institute of Corporate Directors.

  • Pierre Laurin,

    Mr. Pierre Laurin is a senior executive with more than 35 years of experience in the pharmaceutical and biotechnology industry. He founded Prometic Life Sciences Inc. in 1994 and took the company public on the Toronto Stock Exchange in 1998. He served as President and Chief Executive Officer of the Corporation since its inception until December 2018 during which period he raised close to $1 billion in equity, debt financing and multinational funding. Mr. Laurin's corporate development achievements include the successful closing of multiple licensing agreements and partnering agreements with multinationals, including two strategic agreements with the American Red Cross, which led to commercial applications and blood derived therapeutics. Mr. Laurin's prior experience also includes positions with various pharmaceutical companies, including Nordic Laboratories (now Sanofi) where he played a pivotal role in the development and commercial success of Cardizem® in Canada and in the UK.

    He is currently a board member of Innodem Neurosciences Inc., Innovon Pharmaceuticals Inc. and Invhealth Capital Inc. Mr. Laurin holds a Bachelor degree in Pharmacy and an MSc degree in Pharmaceutical Sciences from the University of Montreal.

  • Claude LeDuc,

    Mr. LeDuc has cumulated 32 years of senior executive, CEO, COO experience with private and Fortune 500 medical device and bio-pharma companies. He has spent 22 years in the musculoskeletal market, having occupied senior positions with Genzyme, Biomatrix, Serono and BioSyntech. He has raised more than $50 million in public & private financings after taking BioSyntech public on the TSX-V exchange as its CEO in 2004. During his 5year tenure as BioSyntech CEO, he has worked closely with Ecole Polytechnique who is an active partner in the development of Ortho's proprietary platform, and was directly involved in the clinical and regulatory development of the BST-CarGel product which was later acquired by Orthopaedic giant, Smith & Nephew.

  • Patrick O'Donnell,

    Patrick O'Donnell is the President and Chief Executive Officer of HD LifeSciences, a prominent life sciences executive with over 25 years of experience guiding companies in both the pre-commercial and commercial stages. Mr. O'Donnell brings a comprehensive understanding of the medical device, orthobiologics and biomaterial industries in the orthopedic, spine, neurosurgery, and sports medicine markets.

    Prior to his role at HD LifeSciences, he was Executive Vice-President & General Manager of Commercial Operations for Bonesupport A.B.;Co-Founder and CEO for Proteothera, Inc.; President and CEO for Histogenics Corporation / Prochon Biotech, Inc., Director of Global Marketing for Confluent Surgical, Inc., and sales and marketing positions of escalating responsibility for Johnson & Johnson / DePuy Spine. Patrick graduated from the University of Wisconsin-Madison.

  • Howard P. Walthall,

    Mr. Walthall is a seasoned Life Sciences executive with an extensive background in Regenerative Medicine, Orthopedics and Advanced Wound Care. During his career, he oversaw multiple highly successful product development projects and new product launches and led a growing company to successful exit by strategic acquisition. Mr. Walthall began his career in 2000 as an attorney at Burr & Forman LLP where he specialized in 10 intellectual property and technology-related litigation and transactional work. In 2011, Mr. Walthall became President and CEO of NuTech Spine, Inc. and later held concurrent President and CEO positions at NuTech Medical, Inc. and NuTech Spine Inc. ("NuTech"), companies specialized in the business of advanced surgical biologics and wound care. After a successful exit via the acquisition of NuTech by Organogenesis, Inc. ("Organogenensis"), Mr. Walthall became Executive Vice President, Strategy and Market Development at Organogenesis where he led Sales, Marketing and R&D for the Surgical and Sports Medicine (SSM) product lines. In 2020, Mr. Walthall founded and is now CEO of Lumiheal Therapeutics, Inc., a company which develops and commercializes a patented technology that uses fluorescent light energy (FLE) to heal chronic and acute wounds, burns, and surgical incisions. Mr. Walthall holds a Bachelor of Science in Engineering (B.S.E.) from Duke University, Durham, NC and a Juris Doctor (JD) from Samford University – Cumberland School of Law, Birmingham, AL.

  • Tim Cunningham,

    Mr. Cunningham brings over 30 years of extensive finance and operations leadership experience in the biotechnology and software industries as a CFO with a demonstrated record of success in building start-up enterprises into industry leaders and scaling larger entities globally. His expertise includes financial & strategic planning, P&L management and execution, acquisitions & divestures, raising equity and debt and post-merger integration. Throughout his career, Mr. Cunningham has raised more than $500M in private and public equity as well as debt. Mr. Cunningham started his career in public accounting with KPMG in NYC and later with PWC in Boston. Prior to joining Danforth Advisors, he served as CFO at Organogenesis where he took the company public in 2018, raising $144M in equity and $100M in debt over his tenure. He built the teams, systems, processes and procedures leading to revenue growth from $98M in 2016 to a record $270M TTM in 2020 and the highest rating from each of the sell-side analysts Mr. Cunningham holds an MBA from Boston University, a BS in Accounting from Boston College and is a CPA in the states of New York & Florida

Scientific Advisory Board

  • Prof Michael Buschmann

    Mike is Chair of Bioengineering at George Mason University in Fairfax VA, USA. From 1994 to 2017 he was a Professor at Polytechnique Montréal. Dr. Buschmann has a Ph.D. in Medical Engineering and Medical Physics from MIT and Harvard University, with postdoctoral training in cartilage repair and histology completed at the University of Bern in Switzerland. Since 1994 he conducted a multidisciplinary research program at Polytechnique Montréal that focuses on the use of biomaterials to repair meniscus, rotator cuff and cartilage and to deliver mRNA and small interfering RNA using nanovectors.

  • Prof Caroline Hoemann

    Caroline Hoemann is a Professor of Bioengineering at George Mason University, whose research laboratory is located in the Institute for Advanced Biomedical Research in Manassas VA, USA. Dr. Hoemann has a M.Sc. in Applied Biology and a Ph.D. in Toxicology from MIT. From 2006 to 2017 she was a professor at Polytechnique Montréal. During this time, she was awarded 3 consecutive career fellowships from the Fonds de la Recherche Santé du Quebec (FRQ-S): Junior II, Senior, and National, in recognition of her research in biomaterial devices for articular cartilage repair. Her preclinical research also includes work on bone void fillers and novel anti-inflammatory treatments that protect soft tissues in the knee joint. Her laboratory has made important advances in understanding the role of inflammation and innate immunity in biomaterial-guided tissue regeneration.

Clinical Advisory Board

  • Dr. Scott Rodeo

    Dr. Scott Rodeo is Professor of orthopedic Surgery at Weill Medical College of Cornell University and is an Attending Surgeon at the New York-Presbyterian Hospital and the Hospital for Special Surgery, where he is Co-Chief Emeritus of the Sports Medicine and Shoulder Service and Co-Director of the Tissue Engineering, Regeneration and Repair Program.

    He is Head Team Physician for the New York Giants Football Team. Rodeo served as a Team Physician for the United States Olympic Team in 2004, 2008, and 2012. His clinical practice involves orthopedic sports medicine, with specialty interest in complex knee reconstruction (ligament, meniscus and cartilage surgery), tendon repair in the shoulder and other joints, and shoulder instability. Rodeo graduated cum laude from Stanford University, where he completed his undergraduate work while competing on the Stanford Swimming Team. He completed medical school graduating with honors from Cornell University Medical College.

  • Dr. Jack Farr

    Dr. Jack Farr's orthopedic Focus includes knee restoration surgery, cartilage restoration, sports medicine and partial knee replacement.

    He attended Indiana University School of Medicine and completed his residency in orthopedic surgery at Indiana University School of Medicine. He is Board Certified by the American Board of orthopedic Surgeons, and is affiliated with the American Academy of orthopedic Surgeons, American orthopedic Society for Sports Medicine, International Cartilage Repair Society. His hospital affiliations include Indiana orthopedic Hospital, St. Vincent Hospital, Community Hospital South. He is also a voluntary Clinical Professor of orthopedic Surgery IU Medical Center; Director, OrthoIndy Sports Medicine Fellowship; Director, Cartilage Restoration of Center of Indiana and Vice President, Patellofemoral Foundation.

  • Dr. Martyn Snow

    Dr. Martyn Snow is a Consultant orthopedic Surgeon at The Royal orthopedic Hospital, UK.

    Professor Snow's interests include all aspects of shoulder surgery. In particular, arthroscopic procedures such as rotator cuff repair, shoulder stabilisations, capsular release for frozen shoulder and ACJ injuries. He also performs shoulder replacement for arthritis of the shoulder.

    He has a major interest in sporting injuries of the knee, including Anterior and Posterior Cruciate Ligament reconstruction. He treats all aspects of cartilage injuries in the young adult, using the full spectrum of cartilage regeneration techniques, osteotomy, unicondylar and total knee replacement.

    Professor Snow has over 30 publications in various International medical journals, has written 4 book chapters on knee and shoulder injuries and has presented over 50 papers at various national and International meetings.

    He very active in the research community and is currently chief investigator in a number on-going trials. His current areas of interest include, the use of stem cells in cartilage repair, improving tendon healing in rotator cuff repair and functional improvements following ACL reconstruction.

    He is a graduate of Edinburgh University and undertook his Registrar training in the Manchester region. He spent 18 months on fellowship in North America, 12 months in Halifax, Nova Scotia undertaking a Sports Medicine fellowship at the Sports Medicine Clinic of Nova Scotia. He subsequently spent 6 months at the Holand orthopedic and Arthritic Centre in Toronto, gaining further experience in Shoulder and Knee surgery. In 2006 he completed an MSc in orthopedic Engineering from Cardiff University. Professor Snow has since designed his own fixation device for use in ACL reconstruction, which is currently in use by orthopedic surgeons world wide.

  • Dr. Jacques Toueg

    Dr. Toueg received his B.Sc. in physiotherapy from McGill University, his M.D. from Université de Montreal and completed a fellowship in Sports Medicine and Arthroscopic Surgery at the University of British Columbia.

    Dr. Toueg, a practicing Orthopedic Surgeon and Director of the Montreal Institute for Special Surgery, specializes in sports medicine and in arthroscopic surgery of the shoulder and knee. He is the chief medical officer of la coupe Rogers’s Cup and the National Tennis training center in Montreal. Dr. Toueg has treated numerous athletes from national teams, professional boxers, as well as a number of players from the National Hockey League, the Major Junior Hockey League of Quebec and the Canadian Football League. Since 2010, he has co-hosted the Radio-Canada program, The Doctors.